【導讀】1:ChiesaE,BiniT,AdorniF,CapettiA,RizzardiniG,FaggionI,MussiniC,SollimaS,MelziS,BongiovanniM,TordatoF,CicconiP,CastelnuovoB,Rusconi. S,d'ArminioMonforteA.2:VanLeeuwenR,KatlamaC,MurphyRL,SquiresK,GatellJ,HorbanA,Clotet. B,StaszewskiS,VanEedenA,ClumeckN,MoroniM,PaviaAT,SchmidtRE,Gonzalez-LahozJ,MontanerJ,AntunesF,GulickR,BanhegyiD,VanDerValkM,ReissP,VanWeertL,VanLethF,JohnsonVA,SommadossiJP,LangeJM.AIDS.2020May2;17(7):987-999.3:AnanworanichJ,NueschR,TeeratakulpisarnS,SrasuebkulP,ChuenyamT,SiangphoeU,UngsedhaphandC,PhanuphakP,RuxrungthamK.4:CasauNC,GlesbyMJ,PaulS,GulickRM.HIV-InfectedPatients.5:LeitchH,TrudeauM,RoutyJP.chemotherapy.6:WuTD,SchifferCA,GonzalesMJ,TaylorJ,KantorR,ChouS,IsraelskiD,ZolopaAR,FesselWJ,ShaferRW.JVirol.2020Apr;77(8):4836-47.7:UrbanAW,BeanP,AzizD,GrazianoFM,NeudeckBL.8:SufkaSA,FerrariG,GryszowkaVE,WrinT,FiscusSA,TomarasGD,StaatsHF,PatelDD,SempowskiGD,HellmannNS,WeinholdKJ,HicksCB.Control.9:DinsmoorMJ,ForrestST.pregnancy.10:PauseA,KukoljG,BaileyM,BraultM,DoF,HalmosT,LagaceL,MauriceR,MarquisM,McKercherG,PellerinC,PiloteL,ThibeaultD,LamarreD.CvirusRNA.

　　

【正文】 848286 [PubMed indexed for MEDLINE] 71: Pereira AS, Kenney KB, Cohen MS, Eron JJ, Tidwell RR, Dunn JA. Determination of amprenavir, a HIV1 protease inhibitor, in human seminal plasma using highperformance liquid chromatographytandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jan 25。766(2):30717. PMID: 11824819 [PubMed indexed for MEDLINE] 72: Calista D, Morri M, Stagno A, Boschini A. Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor. Am J Clin Dermatol. 2020。3(1):5962. PMID: 11817969 [PubMed indexed for MEDLINE] 73: Yerly S, Rickenbach M, Popescu M, Taffe P, Craig C, Perrin L. Drug resistance mutations in HIV1infected subjects during protease inhibitorcontaining highly active antiretroviral therapy with nelfinavir or indinavir. Antivir Ther. 2020 Sep。6(3):1859. PMID: 11808753 [PubMed indexed for MEDLINE] 74: Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, Cesar D, Abe K, Hanley MB, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK. CD4+ T cell kiics and activation in human immunodeficiency virusinfected patients who remain viremic despite longterm treatment with protease inhibitorbased therapy. J Infect Dis. 2020 Feb 1。185(3):31523. PMID: 11807713 [PubMed indexed for MEDLINE] 75: Davis DA, ReadConnole E, Pearson K, Fales HM, Newb FM, Moskovitz J, Yarchoan R. Oxidative modifications of kynostatin272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activity in monocytes/macrophages. Antimicrob Agents Chemother. 2020 Feb。46(2):4028. PMID: 11796349 [PubMed indexed for MEDLINE] 76: Youle M, Tyrer M, Fisher M, Lampe F, Wilson D, Ransom D, Story A, Mocroft A, Loveday C, Johnson MA, Phillips AN. Brief report: twoyear oute of a multidrug regimen in patients who did not respond to a protease inhibitor regimen. J Acquir Immune Defic Syndr. 2020 Jan 1。29(1):5861. PMID: 11782591 [PubMed indexed for MEDLINE] 77: Galli M, Ridolfo AL, Adorni F, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Piazza M, Vaccarezza M, d39。Arminio Monforte A, Moroni M. Body habitus changes and metabolic alterations in protease inhibitornaive HIV1infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2020 Jan 1。29(1):2131. PMID: 11782586 [PubMed indexed for MEDLINE] 78: Yoshimura K, Kato R, Kavlick MF, Nguyen A, Maroun V, Maeda K, Hussain KA, Ghosh AK, Gulnik SV, Erickson JW, Mitsuya H. A potent human immunodeficiency virus type 1 protease inhibitor, UIC94003 (TMC126), and selection of a novel (A28S) mutation in the protease active site. J Virol. 2020 Feb。76(3):134958. PMID: 11773409 [PubMed indexed for MEDLINE] 79: Jackson RM, Russell RB. Predicting function from structure: examples of the serine protease inhibitor canonical loop conformation found in extracellular proteins. Comput Chem. 2020 Dec。26(1):319. PMID: 11765849 [PubMed indexed for MEDLINE] 80: Heintges T, Encke J, zu Putlitz J, Wands JR. Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor. J Med Virol. 2020 Dec。65(4):67180. PMID: 11745930 [PubMed indexed for MEDLINE] 81: Le Moing V, Chene G, Carrieri MP, Alioum A, BrunVezi F, Piroth L, Cassuto JP, Moatti JP, Raffi F, Leport C. Predictors of virological rebound in HIV1infected patients initiating a protease inhibitorcontaining regimen. AIDS. 2020 Jan 4。16(1):219. PMID: 11741159 [PubMed indexed for MEDLINE] 82: Le Moing V, Chene G, Leport C, Lewden C, Duran S, Garre M, Masquelier B, Dupon M, Raffi F. Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virusinfected patients. Clin Infect Dis. 2020 Jan 15。34(2):23947. PMID: 11740714 [PubMed indexed for MEDLINE] 83: Battegay M, Vernazza PL, Bernasconi E, Flepp M, Sendi P, Erb P, Malinverni R, Jaccard C, Menthaler S, Bedoucha V, Hirschel B. Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIVinfected protease inhibitornaive patients. HIV Med. 2020 Jan。2(1):3542. PMID: 11737374 [PubMed indexed for MEDLINE] 84: [No authors listed] Amprenavir: new preparation. Another HIV protease inhibitor: no proven advance. Prescrire Int. 2020 Jun。10(53):702. PMID: 11718166 [PubMed indexed for MEDLINE] 85: Mangum EM, Graham KK. LopinavirRitonavir: a new protease inhibitor. Pharmacotherapy. 2020 Nov。21(11):135263. Review. PMID: 11714208 [PubMed indexed for MEDLINE] 86: Michelet C, Ruffault A, Sebille V, Arvieux C, Jaccard P, Raffi F, Bazin C, Chapplain JM, Chauvin JP, Dohin E, Cartier F, Bellissant E. Ritonavirsaquinavir dual protease inhibitor pared to ritonavir alone in human immunodeficiency virusinfected patients. Antimicrob Agents Chemother. 2020 Dec。45(12):3393402. PMID: 11709314 [PubMed indexed for MEDLINE] 87: Moyle G, Baldwin C, Mandalia S, Comitis S, Burn P, Gazzard B. Changes in metabolic parameters and body shape after replacement of protease inhibitor With efavirenz in virologically controlled HIV1positive persons: singlearm observational cohort. J Acquir Immune Defic Syndr. 2020 Dec 1。28(4):399401. No abstract available. PMID: 11707680 [PubMed indexed for MEDLINE] 88: Masquelier B, Neau D, Chene G, Larbere J, Birac V, Ragnaud JM, Fleury HJ. Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV1 RNA. J Acquir Immune Defic Syndr. 2020 Dec 1。28(4):30912. PMID: 11707665 [PubMed index